WILLIAM K PLUNKETT JR to Tumor Cells, Cultured
This is a "connection" page, showing publications WILLIAM K PLUNKETT JR has written about Tumor Cells, Cultured.
Connection Strength
0.813
-
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011 Jan 06; 117(1):156-64.
Score: 0.054
-
Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin Cancer Res. 2009 Jun 01; 15(11):3760-9.
Score: 0.049
-
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006 Dec 18; 175(6):913-23.
Score: 0.041
-
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia. 2006 Apr; 20(4):610-9.
Score: 0.039
-
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24.
Score: 0.038
-
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol Pharmacol. 2002 Sep; 62(3):680-8.
Score: 0.031
-
Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). Biochem Pharmacol. 2001 Jun 15; 61(12):1497-507.
Score: 0.028
-
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol. 2001 Apr; 59(4):725-31.
Score: 0.028
-
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res. 2001 Feb 01; 61(3):1065-72.
Score: 0.027
-
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Res. 2000 Nov 15; 60(22):6408-15.
Score: 0.027
-
Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000 Sep 21; 407(6802):390-5.
Score: 0.027
-
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 2000 Aug; 14(8):1405-13.
Score: 0.026
-
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res. 2000 Mar; 6(3):773-81.
Score: 0.026
-
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 1997 Jul 01; 90(1):270-8.
Score: 0.021
-
Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA. J Biol Chem. 1996 Aug 09; 271(32):19428-35.
Score: 0.020
-
Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13.
Score: 0.019
-
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res. 1995 Sep; 1(9):1005-13.
Score: 0.019
-
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10.
Score: 0.019
-
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7.
Score: 0.019
-
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995 May; 47(5):1072-9.
Score: 0.018
-
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995; 36(3):181-8.
Score: 0.018
-
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
Score: 0.018
-
Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells. J Biol Chem. 1993 Oct 25; 268(30):22363-8.
Score: 0.017
-
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7.
Score: 0.016
-
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood. 1993 Jan 01; 81(1):143-50.
Score: 0.016
-
Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Biochem Pharmacol. 1992 Nov 03; 44(9):1819-27.
Score: 0.015
-
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012 Feb 19; 14(3):276-86.
Score: 0.015
-
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7.
Score: 0.015
-
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990 Jun 15; 50(12):3675-80.
Score: 0.013
-
Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8.
Score: 0.013
-
Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008 Mar 01; 26(7):1098-105.
Score: 0.011
-
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34.
Score: 0.011
-
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 2003 May 15; 101(10):4098-104.
Score: 0.008
-
Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res. 2001 Dec 15; 61(24):8723-9.
Score: 0.007
-
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl. 2000 Aug 18; 745(2):421-30.
Score: 0.007
-
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood. 1998 Mar 01; 91(5):1742-8.
Score: 0.006
-
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol. 1997 Nov; 52(5):798-806.
Score: 0.005
-
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res. 1997 Apr 15; 57(8):1487-94.
Score: 0.005
-
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996 Mar; 10(3):456-9.
Score: 0.005
-
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol. 1996; 37(5):445-50.
Score: 0.005
-
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol. 1996; 38(3):261-8.
Score: 0.005
-
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol. 1994; 34(3):249-56.
Score: 0.004
-
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 Suppl 2:79-83.
Score: 0.004